ClinicalTrials.gg
Not yet recruitingNCT07331077Updated Jun 16, 2026

A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial

An interventional study of Accelerometry and Aerobic Exercise in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage IIIA Breast Cancer AJCC v8, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Breast Neoplasms by Mayo Clinic — 30 open to participants now, 41 under way, 1 of them phase 3. Breast Neoplasms · Mayo Clinic.

Planned enrollment
79th of 97
10 · median 48
Started
2026
with 3 others
No phase
43 of 160
9 open now
Primary completion
2027-11
later than 16 of 40 live
Registered
156th of 160
by date

Among the 160 studies in Breast Neoplasms by Mayo Clinic, this one is the 79th largest by planned enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2026, is one of 43 with no phase, reaches primary completion later than 16 of the 40 other live ones, and was the 156th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 160 studies in Breast Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Breast Neoplasms by Mayo Clinic, or all of them as a file.
02

Study summary

This clinical trial compares a physical activity program to a health education program for improving memory and attention in Hispanic women who are 50 years of age or older and are newly-diagnosed with stage I-IIIa breast cancer. Compared to non-Hispanic White breast cancer survivors (BCS), Hispanic BCS report greater depressive symptoms, emotional distress, anxiety, fear of recurrence, pain, fatigue, and financial toxicity, in addition to more cancer-related psychosocial needs and lower quality of life and social well-being. Cancer-associated cognitive decline (CACD) is a related symptom that has gained increasing attention in clinical research. Based on disparities in other outcomes, it is likely that Hispanic BCS also experience greater CACD than non-Hispanic White BCS, but interventions targeting CACD in Hispanic BCS are non-existent and critically needed. The benefits of aerobic exercise among BCS are well documented and include improvement in health outcomes that are associated with cognitive function including fatigue, anxiety, depression, and sleep. A physical activity program that includes aerobic exercise may be more effective than simple health education for improving cognitive functions like memory and attention in Hispanic women who are 50 years of age or older and are newly-diagnosed with stage I-IIIa breast cancer.

03

Conditions studied

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Cancer-related Cognitive Dysfunction
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PRE-REGISTRATION: Age >= 50 years at time of pre-registration visit according to participant report and/or clinical determination
  • PRE-REGISTRATION: Self-identifies as Hispanic (any race)
  • PRE-REGISTRATION: First time, primary diagnosis of Stage I-IIIa breast cancer according to participant report and/or clinical determination
  • PRE-REGISTRATION: Post-surgery and completed primary treatment (i.e., surgery, chemotherapy, and/or radiation therapy) 3-36 months prior to preregistration according to participant report and/or clinical determination
  • PRE-REGISTRATION: Sedentary except for casual lifestyle recreation, self-reporting no more than 90 minutes per week of moderate-intensity aerobic exercise within the last 6 months
  • PRE-REGISTRATION: Self-reported ability to complete assessments by themselves or with assistance
  • REGISTRATION: Age >= 50 years or older as confirmed via clinical determination
  • REGISTRATION: Self-identifies as Hispanic (any race)
  • REGISTRATION: Able to provide medical record release to confirm eligibility
  • REGISTRATION: First time, primary diagnosis of Stage I-IIIa breast cancer as confirmed via clinical determination
  • REGISTRATION: Post-surgery and completed primary treatment (i.e., surgery, chemotherapy, and/or radiation therapy) 3-36 months prior to pre-registration as confirmed via clinical determination
  • REGISTRATION: No evidence of possible cognitive impairment as assessed using the Telephone Interview of Cognitive status (13-item modified version) (TICS-M; score >= 21)
  • REGISTRATION: Receive physician's clearance to participate in an exercise program

    • NOTE: Individuals with conditions/diagnoses deemed important by the primary investigator will be required to provide clearance for exercise from their cardiologist. Example conditions include:

      • History of major multiple myocardial infarctions (MI)
      • Recent (ECG) changes or recent MI
      • Resting or unstable angina
      • Significant multivessel coronary occlusion (>= 70%) on angiography
      • Uncontrolled and/or serious arrhythmias
      • 3rd degree heart block
      • Acute congestive heart failure or \< 30%
  • REGISTRATION: Ability to complete assessments by themselves or with assistance
  • REGISTRATION: Agree to be randomized

Exclusion criteria

Exclusion Criteria:

  • PRE-REGISTRATION: Stage 0 breast cancer diagnosis OR disease
  • PRE-REGISTRATION: Currently receiving or \< 3 months since receiving chemotherapy or radiation therapy for cancer, or greater than 36 months post primary treatment
  • PRE-REGISTRATION: Planned surgery during the intervention period
  • PRE-REGISTRATION: Secondary cancer diagnosis (excluding non-invasive skin cancers, carcinoma-in-situ for any cancer)
  • PRE-REGISTRATION: Unable to regularly attend the study locations for intervention sessions and data collection
  • PRE-REGISTRATION: Unwilling to return to enrolling institution for follow-up
  • PRE-REGISTRATION: Self-reported inability to walk without assistance or devices
  • PRE-REGISTRATION: Self-reported pregnancy
  • REGISTRATION: History of stroke, , other neurological disorders, or brain surgery involving tissue removal as confirmed via clinical determination
  • REGISTRATION: TICS-M score (\< 21) during baseline procedures
  • REGISTRATION: Not able to provide physician re-clearance for exercise if required based upon clinically significant baseline exercise test (as determined by and blood pressure monitoring)
  • REGISTRATION: to functional magnetic resonance imaging (fMRI) in accordance with the Mayo Clinic Department of Radiology safety protocols
  • REGISTRATION: Clinically significant magnetic resonance imaging (MRI) scan as determined by physician review in which the following is advised via radiologist overread: remarkable/abnormal limited diagnostic brain image with recommended medical follow-up
  • REGISTRATION: Enrolled in another physical activity program
  • REGISTRATION: Unable to walk without assistance or devices
  • REGISTRATION: Unwilling to complete study requirements
  • REGISTRATION: Unwilling to be randomized to the exercise group or health education group
  • REGISTRATION: Unable to regularly attend study locations for intervention sessions and data collection
  • REGISTRATION: Unwilling to return to enrolling institution for follow-up
  • REGISTRATION: Unable to complete the study in English or Spanish
  • REGISTRATION: Self-reported pregnancy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Arm A (walking program)

    Patients participate in walking sessions over 60-75 minutes per week in weeks 1-2, 70-90 minutes per week in weeks 3-4, 90-120 minutes per week in weeks 5-8, 120-135 minutes per week in weeks 9-12, 135-150 minutes per week in weeks 13-16, and 150+ minutes per week in weeks 17-24. Patients also undergo fMRI throughout the trial.

    Procedure: Accelerometry · Other: Aerobic Exercise · Other: Electronic Health Record Review · Procedure: Functional Magnetic Resonance Imaging · Other: Gait Assessment Test · Other: Interview · Other: Neurocognitive Assessment · Other: Physical Performance Testing · Other: Questionnaire Administration

  • Active comparator
    Arm B (health education)

    Patients receive health education including monthly classes/webinars for up to 9 sessions and informational materials (PDFs, videos, podcasts, and/or subscription to Mayo Clinic Health Letter). Patients also undergo fMRI throughout the trial.

    Procedure: Accelerometry · Other: Electronic Health Record Review · Procedure: Functional Magnetic Resonance Imaging · Other: Gait Assessment Test · Behavioral: Health Education · Other: Neurocognitive Assessment · Other: Physical Performance Testing · Other: Questionnaire Administration

Interventions

  • ProcedureAccelerometry

    Ancillary studies

  • OtherAerobic Exercise

    Participate in walking program

    Also known as: Aerobic Activity

  • OtherElectronic Health Record Review

    Ancillary studies

  • ProcedureFunctional Magnetic Resonance Imaging

    Undergo fMRI

    Also known as: fMRI, Functional MRI

  • OtherGait Assessment Test

    Ancillary studies

  • BehavioralHealth Education

    Receive health education

  • OtherInterview

    Ancillary studies

  • OtherNeurocognitive Assessment

    Ancillary studies

  • OtherPhysical Performance Testing

    Ancillary studies

    Also known as: Physical Fitness Testing, Physical Function Testing

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in inhibitory control

    Change in interference score on Stroop task, with positive values indicating greater inhibitory control

    Time frame: Baseline to post-intervention (month 6)

  2. Change in cognitive flexibility

    Change in accuracy on Shifting Attention task, with higher values indicating greater cognitive flexibility

    Time frame: Baseline to post-intervention (month 6)

  3. Change in executive function processing

    Change in reaction time on Shifting Attention task, with lower values indicating greater cognitive flexibility

    Time frame: Baseline to post-intervention (month 6)

  4. Change in short-term memory

    Change in accuracy on Visual Memory task, with higher accuracy indicating greater short-term memory

    Time frame: Baseline to post-intervention (month 6)

  5. Change in verbal memory

    Change in number recalled on Hopkins Verbal Learning task, with higher values indicating greater verbal memory

    Time frame: Baseline to post-intervention (month 6)

  6. Change in working memory

    Change in reaction time the 4-part Continuous Performance task, with lower values indicating greater working memory

    Time frame: Baseline to post-intervention (month 6)

  7. Change in processing speed

    Change in reaction time on Symbol Digit Coding task, with lower values indicating greater processing speed

    Time frame: Baseline to post-intervention (month 6)

  8. Change in attention

    Change in choice reaction time on Continuous Performance task, with lower values indicating greater sustained attention

    Time frame: Baseline to post-intervention (month 6)

  9. Change in brain volume

    Change in mean cortical thickness of brain regions of interest as measured by an anatomic MRI brain scan

    Time frame: Baseline to post-intervention (month 6)

  10. Change in white matter integrity

    Change in fractional anisotropy as measured by diffusion MRI.

    Time frame: Baseline to post-intervention (month 6)

  11. Change in resting state functional connectivity

    Change in within-network pairwise correlation estimates as measured using a multiband echo planar imaging (mb-EPI) functional MRI sequence

    Time frame: Baseline to post-intervention (month 6)

  12. Change in self-reported cognitive function - FACT-Cog

    The perceived cognitive impairments subscale of the Functional Assessment in Cancer Therapy - Cognition (FACT-Cog) will be used to measure self-reported cognition. Scores range from 0-72, with higher scores indicating better cognitive function.

    Time frame: Baseline to post-intervention (month 6)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2027, 13 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 13 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 9, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07331077
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Diane K. Ehlers, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion